Table 3.
Left ventricular function and perfusion
| Bone marrow cell group | |||||||||||
| Baseline (N = 19) |
3-month follow-up
(N = 18) |
12-month follow-up
(N = 14) |
|||||||||
| Absolute value (mean ± SD) |
Absolute change (mean ± SD) |
Estimated difference (mean) |
95% CI | P-value | Absolute change (mean ± SD) |
Estimated difference (mean) |
95% CI | P-value | |||
| Lower | Upper | Lower | Upper | ||||||||
| EFr (%) | 32.6 ± 12.3 | −1.0 ± 7.0 | −0.7 | −3.5 | 2.1 | 0.61 | 0.6 ± 4.3 | 0.2 | −1.7 | 2.2 | 0.81 |
| EFs (%) | 32.2 ± 12.2 | −1.9 ± 7.6 | −1.4 | −4.2 | 1.4 | 0.32 | 1.0 ± 7.5 | 1.2 | −2.0 | 4.5 | 0.45 |
| ESV (ml) | 220 ± 126 | −3.7 ± 23.4 | −4.3 | −16.8 | 8.2 | 0.49 | 2.9 ± 30.6 | 4.5 | −12.9 | 22.0 | 0.59 |
| EDV (ml) | 309 ± 131 | −6.7 ± 26.5 | −6.5 | −21.4 | 8.4 | 0.39 | 3.7 ± 36.6 | 0.5 | −22.1 | 23.1 | 0.96 |
| SSS | 46.4 ± 7.4 | −0.4 ± 1.5 | −0.5 | −1.2 | 0.3 | 0.20 | 0.2 ± 2.5 | −0.1 | −1.3 | 1.0 | 0.86 |
| SRS | 45.1 ± 7.6 | −0.1 ± 1.9 | −0.1 | −1.1 | 0.9 | 0.85 | 0.4 ± 2.4 | −0.1 | −1.4 | 1.3 | 0.87 |
| SDS | 1.3 ± 2.2 | −0.4 ± 1.0 | −0.6 | −1.2 | −0.01 | 0.05 | −0.1 ± 1.8 | −0.3 | −1.1 | 0.5 | 0.48 |
| Placebo group | |||||||||||
| Baseline (N = 20) |
3-month follow-up
(N = 18) |
12-month follow-up
(N = 13) |
|||||||||
| Absolute value (mean ± SD) |
Absolute change (mean ± SD) |
Estimated difference (mean) |
95% CI | P-value | Absolute change (mean ± SD) |
Estimated difference (mean) |
95% CI | P-value | |||
| Lower | Upper | Lower | Upper | ||||||||
| EFr (%) | 29.0 ± 9.7 | 0.8 ± 4.8 | 0.7 | −2.1 | 3.5 | 0.62 | 2.6 ± 2.7 | 2.8 | 0.7 | 4.8 | 0.01 |
| EFs (%) | 29.0 ± 9.0 | −0.3 ± 4.6 | −0.6 | −3.3 | 2.2 | 0.68 | 2.1 ± 5.1 | 0.9 | −2.3 | 4.2 | 0.56 |
| ESV (ml) | 221 ± 105 | −3.7 ± 34.0 | −3.8 | −16.2 | 8.7 | 0.55 | −9.7 ± 31.5 | −6.8 | −24.7 | 11.0 | 0.44 |
| EDV (ml) | 299 ± 110 | −2.2 ± 43.4 | −2.0 | −16.9 | 12.8 | 0.78 | −2.2 ± 38.2 | 5.0 | −18.0 | 28.1 | 0.65 |
| SSS | 46.8 ± 4.5 | −0.9 ± 1.9 | −0.8 | −1.6 | −0.1 | 0.03 | −0.5 ± 2.2 | −0.7 | −1.9 | 0.5 | 0.23 |
| SRS | 44.0 ± 5.1 | 0.3 ± 1.0 | 0.4 | −0.3 | 1.0 | 0.25 | 0.4 ± 1.5 | 0.3 | −0.7 | 1.32 | 0.56 |
| SDS | 2.7 ± 3.1 | −1.2 ± 1.7 | −1.1 | −1.7 | −0.45 | <0.01 | −0.8 ± 1.9 | −0.9 | −1.7 | −0.1 | 0.04 |
| Group difference (treatment effect) | |||||||||||
| Baseline | 3-month follow-up | 12-month follow-up | |||||||||
| Absolute difference (mean) |
Absolute difference in change (mean) |
Estimated difference (mean) |
95% CI | P-value | Absolute difference in change (mean) |
Estimated difference (mean) |
95% CI | P-value | |||
| Lower | Upper | Lower | Upper | ||||||||
| EFr (%) | 3.7 | −1.8 | −1.4 | −5.4 | 2.5 | 0.47 | −2.0 | −2.5 | −5.4 | 0.3 | 0.08 |
| EFs (%) | 3.2 | −1.6 | −0.8 | −4.6 | 3.0 | 0.67 | −1.1 | 0.3 | −4.1 | 4.7 | 0.89 |
| ESV (ml) | −0.7 | 0.0 | −0.5 | 18.1 | 17.0 | 0.44 | 12.5 | 11.4 | −13.5 | 36.3 | 0.36 |
| EDV (ml) | 10.8 | −4.6 | −4.4 | −25.5 | 16.6 | 0.68 | 5.9 | −4.5 | −36.8 | 27.7 | 0.77 |
| SSS | −0.3 | 0.4 | 0.4 | −0.7 | 1.4 | 0.48 | 0.7 | 0.6 | −1.0 | 2.2 | 0.45 |
| SRS | 1.1 | −0.4 | −0.4 | −1.3 | 0.4 | 0.33 | 0.0 | −0.4 | −1.8 | 1.0 | 0.59 |
| SDS | −1.4 | 0.8 | 0.4 | −0.3 | 1.2 | 0.25 | 0.7 | 0.6 | −0.4 | 1.7 | 0.24 |
CI confidence interval, EFr ejection fraction at rest, EFs ejection fraction at stress, ESV end-systolic volume, EDV end-diastolic volume, SSS summed stress score, SRS summed rest score, SDS summed differences score